AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26910661
Drug: Nonanimal stabilized
RxNorm normalized name: nonanal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonanimal stabilized hyaluronic acid injection
Trial: 22135154
Drug: Preoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative antibiotics (cefazolin 1 g given <30 minutes prior to skin incision)
Trial: 22135154
Drug: Intraoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative antibiotics (cefazolin 1 g at cord clamping)
Trial: 22135154
Drug: Preoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative antibiotics or intraoperative antibiotics
Trial: 20194915
Drug: Pregabalin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (600 mg/d after titration over 8 weeks)
Trial: 18538052
Drug: High urinary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High urinary flow rate (10 mL kg(‐1) h(‐1))
Trial: 18538052
Drug: Low urinary
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low urinary flow rate (3 mL kg(‐1) h(‐1))
Trial: 10857818
Drug: Heparin-surface-modified (HSM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-surface-modified (HSM) intraocular lenses
Trial: 8853141
Drug: Low-dose systemic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose systemic administration of heparin (2,500 units)
Trial: 47280
Drug: Indoprofen 200
RxNorm normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indoprofen 200 mg
Trial: 6384073
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate (ASA) 500 mg
Trial: 6384073
Drug: Lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetylsalicylate (ASA) 1500 mg
Trial: 30993748
Drug: Simtuzumab (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simtuzumab (combined treatment groups from two phase 2b trials)
Trial: 23281759
Drug: 0.03 mg
RxNorm normalized name: biotin 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg biotin/kg
Trial: 23281759
Drug: 0.09 mg
RxNorm normalized name: camphor 0.09 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.09 mg biotin/kg
Trial: 23281759
Drug: 0.12 mg
RxNorm normalized name: iodine 0.12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12 mg biotin/kg
Trial: 23281759
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg biotin/kg
Trial: 23281759
Drug: 0.18 mg
RxNorm normalized name: naloxone 0.18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.18 mg biotin/kg
Trial: 23281759
Drug: 0.21 mg
RxNorm normalized name: albuterol 0.21 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.21 mg biotin/kg
Trial: 20731476
Drug: Guanfacine ER
RxNorm normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine ER (1-4 mg once daily)
Trial: 17035721
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement + topical formulations
Trial: 11214732
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dietary supplement)
Trial: 3031154
Drug: Oral dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dextroamphetamine with oral thymoxamine (alpha‐noradrenergic antagonist)
Trial: 26827250
Drug: SHUTi (online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHUTi (online insomnia program based on cognitive behavioural therapy for insomnia)
Trial: 16238587
Drug: Salbutamol/fluticasone 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol/fluticasone 500 microg/dose, each combined dose administered every 15 min
Trial: 30909945
Drug: AA supplement
RxNorm normalized name: Amino Acids Oral Powder for Suspension [EAA SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA supplement for 15 days prior to the race
Trial: 30909945
Drug: Non-AA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-AA group (no supplement)
Trial: 25775052
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus tirofiban
Trial: 11108748
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator (rtPA)
Trial: 19879462
Drug: Clinical assessment
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical assessment to guide therapy
Trial: 7483087
Drug: Ranitidine hydrochloride
RxNorm normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine hydrochloride (100 mg IV twice daily for four days, followed by 150 mg orally twice daily for five days)
Trial: 20029974
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant treatment (Control)
Trial: 2106334
Drug: Prostacyclin (PGI2)
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (PGI2) infusion before and during CPB
Trial: 2109927
Drug: Prostacyclin (PGI2)
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (PGI2) infusion
Trial: 6117681
Drug: Neither antibiotics
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither antibiotics nor myringotomy
Trial: 6117681
Drug: Both antibiotics
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both antibiotics and myringotomy
Trial: 23541571
Drug: Elevated pretreatment
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elevated pretreatment serum LDH level (≥245.0 U/L)
Trial: 17109335
Drug: Vaccine (rAd5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (rAd5 vector HIV-1 candidate vaccine) at dose levels of 10^9 (n=10), 10^10 (n=10), or 10^11 (n=10) particle units
Trial: 17109335
Drug: Vaccine (rAd5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (rAd5 vector HIV-1 candidate vaccine)
Trial: 11758237
Drug: Meropenem 500
RxNorm normalized name: meropenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 500 mg every 12 hours (or 1g every 12 hours if necessary)
Trial: 31711605
Drug: i.v. dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. dexamethasone 8 mg
Trial: 24067888
Drug: Neridronate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate (100 mg, monthly i.v.)
Trial: 24067888
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg, standard therapy)
Trial: 20831543
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 or 30 mg daily) for 3 months
Trial: 20831543
Drug: Pioglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone treatment in post-menopausal women
Trial: 12135281
Drug: Oral ARTS
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ARTS (135 mg; 352 micromol)
Trial: 12135281
Drug: Oral DHA
RxNorm normalized name: Atabex DHA Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral DHA (120 mg; 422 micromol)
Trial: 12135281
Drug: Hepatic bioavailability
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic bioavailability of ARTS (39 microM)
Trial: 12135281
Drug: Hepatic bioavailability
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic bioavailability of DHA in ARTS perfusions (35 microM)
Trial: 18691193
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (no Rx)
Trial: 15231013
Drug: Raloxifene (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (combined doses of 60 mg/day and 120 mg/day)
Trial: 10955700
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 100 microg daily
Trial: 10955700
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 200 microg daily
Trial: 10999870
Drug: Evening medication
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening medication (all groups)
Trial: 10999870
Drug: Morning medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning medication (all groups)
Trial: 31828172
Drug: Shenqi pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi pollen capsules (SPCs) for 7 weeks
Trial: 31828172
Drug: Shenqi pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi pollen capsules (SPCs)
Trial: 18332764
Drug: Immediate placement
RxNorm normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate placement condition (46 implants)
Trial: 15726322
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving systemic antimicrobial treatment
Trial: 15726322
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without prior antibiotic treatment
Trial: 12904977
Drug: Lithium augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium augmentation therapy
Trial: 8932071
Drug: 10 units
RxNorm normalized name: Omnipod GO 10 Units/Day Pods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 units heparin/ml saline (HS)
Trial: 1859059
Drug: Albuterol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (100 micrograms/puff, three times two puffs)
Trial: 27206549
Drug: Arabinoxylan-oligosaccharide (AXOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arabinoxylan-oligosaccharide (AXOS) 4 × 9.4 g
Trial: 27206549
Drug: Maltodextrin (placebo)
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (placebo) 4 × 10 g
Trial: 3294614
Drug: Captopril at
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril at a dose of 25 mg twice a day
Trial: 3294614
Drug: Nadolol at
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nadolol at a dose of 80 mg once a day
Trial: 3294614
Drug: Frusemide at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide at a dose of 25 mg once a day
Trial: 24106141
Drug: Cadazolid (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadazolid (multiple doses)
Trial: 22800086
Drug: High-dose antioxidant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose antioxidant tablets
Trial: 20849868
Drug: Protein shake
RxNorm normalized name: Ensure High Protein Shake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein shake (AUC=37,024±3518nmol/L min)
Trial: 20849868
Drug: Fat shake
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat shake (AUC=35,977±3562nmol/L min)
Trial: 20849868
Drug: Carbohydrate shake
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate shake (AUC=47,310±3667nmol/L min)
Trial: 20849868
Drug: Water (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (control condition) (AUC=32,784±1683nmol/L min)
Trial: 11473863
Drug: Early reversal
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 2 min after 1.5 mg/kg rapacuronium
Trial: 11473863
Drug: Late reversal
RxNorm normalized name: edrophonium chloride Injectable Solution [Reversol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 25% T1 recovery after 1.5 mg/kg rapacuronium
Trial: 7825998
Drug: Methylprednisolone at
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone at 30 mg/kg i.v. for 3 days followed by 20 mg/kg for 4 days
Trial: 3387687
Drug: Tartrazine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tartrazine (up to 25 mg)
Trial: 3387687
Drug: Tartrazine (50-3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tartrazine (50-3,000 mg)
Trial: 14633567
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (group G, n = 10)
Trial: 8478309
Drug: Dirithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dirithromycin (500 mg, two tablets once daily)
Trial: 24833256
Drug: Comparator antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator antibiotics
Trial: 3709640
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg disopyramide i.v.
Trial: 3709640
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg atenolol i.v.
Trial: 25720546
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole 150 mg
Trial: 21146678
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg clopidogrel
Trial: 29442148
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg ticagrelor
Trial: 23102968
Drug: 9-phage cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-phage cocktail at a dose of 3×10(7) plaque-forming units
Trial: 23102968
Drug: 9-phage cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-phage cocktail (both doses)
Trial: 18613991
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention (specialty advice and evidence-based messages regarding medication management for cardiovascular risk)
Trial: 11927130
Drug: Subcutaneous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous unfractionated heparin (UH) administered in two to three subcutaneous doses adjusted to activated partial thromboplastin time (APTT)
Trial: 30979042
Drug: Low-Intensity Cognitive
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Cognitive Behavior Therapy (LI-CBT) mHealth-supported intervention
Trial: 21268101
Drug: Trospium XR
RxNorm normalized name: trospium Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospium XR 60 mg once daily for 12 weeks
Trial: 18955519
Drug: BILR 355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILR 355 coadministered with 100 mg ritonavir (RTV) at doses of 5 to 50 mg in a polyethylene glycol solution or 50 to 250 mg as tablets, and 150 mg BID coadministered with 100 mg RTV QD or BID.
Trial: 9242943
Drug: Traditional dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional dialysis using dialyzers with a urea clearance of 170‐180 ml/min
Trial: 9242943
Drug: All hemodialysis
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All hemodialysis treatments
Trial: 2598970
Drug: Intravenous nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nicardipine (D3 nicardipine)
Trial: 2598970
Drug: Intravenous unlabelled
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous unlabelled nicardipine (D0 nicardipine)
Trial: 18754014
Drug: Enteral sterile
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral sterile water (up to 50 ml kg(‐1) per day for 7 days)
Trial: 15317632
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy for insomnia (5 sessions, 7 weeks)
Trial: 26210642
Drug: ISIS‐APO(a)Rx 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS‐APO(a)Rx 200 mg (6 doses)
Trial: 26210642
Drug: ISIS‐APO(a)Rx 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS‐APO(a)Rx 300 mg (6 doses)
Trial: 26210642
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 doses)
Trial: 12723759
Drug: Goshajinkigan, 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goshajinkigan, 7.5 g/day for 3 months
Trial: 2127040
Drug: Pentoxifylline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (2 X 600 mg/d)
Trial: 2127040
Drug: Pentoxifylline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (2 X 600 mg/d) and psychological training
Trial: 12202415
Drug: Intramuscular hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hCG
Trial: 12202415
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen added to progesterone
Trial: 30183430
Drug: Electromagnetic transduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromagnetic transduction therapy (EMTT) + Extracorporeal shock wave therapy (ESWT)
Trial: 30183430
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) with sham-EMTT
Trial: 25744274
Drug: Paricalcitol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (2 µg/day) combined with a liberal sodium diet (∼200 mmol Na(+)/day)
Trial: 25744274
Drug: Paricalcitol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (2 µg/day) combined with dietary sodium restriction (target: 50 mmol Na(+)/day)
Trial: 22567139
Drug: Tablets
RxNorm normalized name: Mesna Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: 11830525
Drug: IFN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN treatment among patients with Δ13
Trial: 2632716
Drug: Alcohol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.75 g/kg body weight, diluted in orange juice)
Trial: 31636806
Drug: L-carnitine-L-tartrate 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine-L-tartrate 1500 mg per day (n = 11)
Trial: 21615472
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied to half of each IH once every other night for 16 weeks
Trial: 17285204
Drug: Tropisetron 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 0.5 mg/m2
Trial: 17285204
Drug: Tropisetron 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 1.0 mg/m2
Trial: 17285204
Drug: Tropisetron 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 1.5 mg/m2
Trial: 17285204
Drug: Tropisetron 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 2.0 mg/m2
Trial: 17285204
Drug: Tropisetron (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (all doses)
Trial: 17285204
Drug: Tropisetron (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (0.5, 1.0, 1.5, 2.0 mg/m2)
Trial: 17285204
Drug: Tropisetron (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (0.5 mg/m2)
Trial: 2207824
Drug: Etomidate (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.2 mg/kg)
Trial: 2545455
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (500 micrograms and above)
Trial: 144508
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of sodium aurothiomalate (150 mg weekly)
Trial: 144508
Drug: Conventional doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional doses of sodium aurothiomalate (50 mg weekly)
Trial: 25396334
Drug: 80 kVp/60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 kVp/60 mL CCTA
Trial: 25396334
Drug: 100 kVp/60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 kVp/60 mL CCTA
Trial: 22994579
Drug: Nutraceutical combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical combination without Orthosiphon stamineus
Trial: 19183308
Drug: Low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat meal (2 g fat, 320 kcal)
Trial: 19183308
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (38 g fat, 640 kcal)
Trial: 10690130
Drug: DCLHb 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb 100 mg kg‐1 i.v.
Trial: 10690130
Drug: DCLHb 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb 200 mg kg‐1 i.v.
Trial: 23344769
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rt-PA (group A)
Trial: 23344769
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg rt-PA (group B)
Trial: 16759048
Drug: Salvage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage therapy with less daily doses